Opioid Addiction News and Research

RSS

New multi-faceted treatment program for young adults addicted to opioid drugs

A multi-faceted treatment program for young adults addicted to opioid drugs was unveiled today at the National Institute on Drug Abuse's Blending Conference in Albuquerque, N.M. This eighth meeting in the series brings together researchers and clinicians so their latest findings can be immediately applied to the needs of patients and their families dealing with addictive disorders.

23 Apr 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

New nursing guideline to enhance improved care for MMT clients

A pregnant woman walks into a hospital in early labour. She feels nauseated and achy; her contractions are 20 minutes apart. There is more to her story than meets the eye. She is on methadone maintenance therapy (MMT) and wasn't able to pick up her daily dose at the pharmacy this morning. Although her story may be hard to believe she is one of the estimated 17,000 clients in Ontario currently receiving MMT.

2 Dec 2009

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

13 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

NIH awards Titan $7.6M grant for Probuphine clinical development

Titan Pharmaceuticals, Inc today announced that the National Institutes of Health (NIH) has awarded a Research and Research Infrastructure Grand Opportunities grant to the company through the American Reinvestment and Recovery Act of 2009 (ARRA). The two year grant for Probuphine clinical development is expected to provide approximately $7.6 million, with the first year award of approximately $ 5.6 million now made available to Titan by the NIH.

3 Oct 2009

Double the number of Australians now being treated for heroin addiction

The latest report from the Australian Institute of Health and Welfare (AIHW) shows in the last decade the number of Australians being treated for heroin, or other opioid, addiction has almost doubled.

22 May 2009

Naltrexone appears to relieve fibromyalgia pain

For Tara Campbell, the onset of her fibromyalgia began slowly with repeated sore throats, fevers and fatigue.

20 Apr 2009

Opioid antagonists show potential for problematic pain

Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.

2 Apr 2009

Opioid antagonists help pain management

Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.

3 Mar 2009

Ondansetron shown to be a viable treatment option for opioid addiction

Scientists at Stanford University School of Medicine have discovered that a commonly available non-addictive drug can prevent symptoms of withdrawal from opioids with little likelihood of serious side effects.

18 Feb 2009

Extended suboxone treatment substantially improves outcomes for opioid-addicted young adults

In the first clinical trial of a medication that was used for an extended time to treat opioid addiction in young adults, participants who received counseling and Suboxone (buprenorphine-naloxone) for 12 weeks had substantially better outcomes than those who received the standard treatment of short-term detoxification and counseling.

4 Nov 2008

Titan Pharmaceuticals updates on Probuphine patent application

Titan Pharmaceuticals, Inc. today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company's method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain.

31 Oct 2008

Methadone shows promise against leukemia

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

3 Aug 2008

Epidemic of pain addressed by leading physicians

The public health problem that needs to be addressed next is the epidemic of pain, according to pain medicine physicians who have come together to discuss the latest in pain research and treatment at the 24th Annual Meeting of the American Academy of Pain Medicine (AAPM), February 12-16 at the Gaylord Palms in Kissimmee (Orlando), Florida.

17 Feb 2008

Office-based buprenorphine treatment for drug abuse shows promise

Patients who receive buprenorphine treatment for opioid addiction in an office-based setting are more likely than those receiving methadone treatment to be young men, new to drug use, and with no history of methadone treatment, Yale School of Medicine researchers report in a study published in Drug and Alcohol Dependence.

28 Jun 2005